INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $434,000 | -27.5% | 16,916 | -27.5% | 0.00% | 0.0% |
| Q2 2020 | $599,000 | +9.1% | 23,328 | -34.7% | 0.00% | 0.0% |
| Q1 2020 | $549,000 | -46.6% | 35,728 | +19.1% | 0.00% | 0.0% |
| Q4 2019 | $1,029,000 | +433.2% | 30,000 | +101.3% | 0.00% | – |
| Q2 2019 | $193,000 | +11.6% | 14,900 | +4.9% | 0.00% | – |
| Q1 2019 | $173,000 | +6.8% | 14,200 | 0.0% | 0.00% | – |
| Q4 2018 | $162,000 | -64.6% | 14,200 | -32.7% | 0.00% | -100.0% |
| Q3 2018 | $458,000 | -31.2% | 21,100 | -44.0% | 0.00% | 0.0% |
| Q2 2018 | $666,000 | -35.6% | 37,700 | -23.2% | 0.00% | -50.0% |
| Q1 2018 | $1,034,000 | +353.5% | 49,100 | +250.7% | 0.00% | – |
| Q1 2017 | $228,000 | -1.3% | 14,000 | -8.5% | 0.00% | – |
| Q4 2016 | $231,000 | +6.9% | 15,300 | +7.7% | 0.00% | – |
| Q3 2016 | $216,000 | – | 14,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |